RNA TARGETING OF MUTATIONS VIA SUPPESSOR tRNAs AND DEAMINASES
US-2021198673-A1 · Jul 1, 2021 · US
Methods of rescuing stop codons via genetic reassignment with ACE-tRNA
US12559749B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12559749-B2 |
| Application number | US-202318137931-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 21, 2023 |
| Priority date | Nov 2, 2017 |
| Publication date | Feb 24, 2026 |
| Grant date | Feb 24, 2026 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
In certain embodiments, the present invention provides a modified transfer RNA (tRNA) comprising a T-arm, a D-arm, an anticodon-arm and an acceptor arm, wherein the T-arm comprises nucleotides that interact with the elongation factor 1 alpha protein, and methods of use thereof. In certain embodiments, the present invention provides a modified transfer RNA (tRNA) comprising a T-arm, a D-arm, an anticodon-arm and an acceptor arm, (a) wherein the anticodon-arm comprises a tri-nucleotide anticodon, wherein the anticodon is 5′-UCA-3′ and recognizes TGA stop codons, and wherein the acceptor arm is operably linked to a arginine, tryptophan or glycine; (b) wherein the anticodon-arm comprises a tri-nucleotide anticodon, wherein the anticodon is 5′-UUA-3′ and recognizes TAA stop codons, and wherein the acceptor arm is operably linked to a glutamine or, glutamate; or (c) wherein the anticodon-arm comprises a tri-nucleotide anticodon, wherein the anticodon is 5′-CUA-3′ and recognizes TAG stop codons, and wherein the acceptor arm is operably linked to a tryptophan, glutamate or glutamine.
First claim
Opening claim text (preview).
What is claimed is: 1 . A modified transfer RNA (tRNA) comprising a T-arm, a D-arm, an anticodon-arm and an acceptor arm, wherein the anticodon-arm comprises a tri-nucleotide anticodon, wherein the anticodon is 5′-UUA-3′ and recognizes TAA stop codons, wherein the acceptor arm is operably linked to a glutamine, and wherein the modified tRNA is encoded by a sequence comprising sequence as set forth in SEQ ID NO: 172. 2 . A modified transfer RNA (tRNA) comprising a T-arm, a D-arm, an anticodon-arm and an acceptor arm, wherein the anticodon-arm comprises a tri-nucleotide anticodon, wherein the anticodon is 5′-UUA-3′ and recognizes TAA stop codons, wherein the acceptor arm is operably linked to a glutamine, and wherein the modified tRNA is encoded by a sequence that comprises the sequence as set forth in SEQ ID NO: 156. 3 . A modified transfer RNA (tRNA) comprising a T-arm, a D-arm, an anticodon-arm and an acceptor arm, wherein the anticodon-arm comprises a tri-nucleotide anticodon, wherein the anticodon is 5′-UUA-3′ and recognizes TAA stop codons, wherein the acceptor arm is operably linked to a glutamine, and wherein the modified tRNA is encoded by a sequence that comprises the sequence as set forth in SEQ ID NO: 161. 4 . A modified transfer RNA (tRNA) comprising a T-arm, a D-arm, an anticodon-arm and an acceptor arm, wherein the anticodon-arm comprises a tri-nucleotide anticodon, wherein the anticodon is 5′-UUA-3′ and recognizes TAA stop codons, wherein the acceptor arm is operably linked to a glutamine, and wherein the modified tRNA is encoded by a sequence that comprises the sequence as set forth in SEQ ID NO: 165. 5 . A modified transfer RNA (tRNA) comprising a T-arm, a D-arm, an anticodon-arm and an acceptor arm, wherein the anticodon-arm comprises a tri-nucleotide anticodon, wherein the anticodon is 5′-UUA-3′ and recognizes TAA stop codons, wherein the acceptor arm is operably linked to a glutamine, and wherein the modified tRNA is encoded by a sequence that comprises the sequence as set forth in SEQ ID NO: 171.
Assignees
Inventors
Classifications
Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links · CPC title
Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant · CPC title
- A61P43/00Primary
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy · CPC title
- C12N15/11Primary
DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity} · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12559749B2 cover?
- In certain embodiments, the present invention provides a modified transfer RNA (tRNA) comprising a T-arm, a D-arm, an anticodon-arm and an acceptor arm, wherein the T-arm comprises nucleotides that interact with the elongation factor 1 alpha protein, and methods of use thereof. In certain embodiments, the present invention provides a modified transfer RNA (tRNA) comprising a T-arm, a D-arm, an …
- Who is the assignee on this patent?
- Univ Iowa Res Found
- What technology area does this patent fall under?
- Primary CPC classification A61P43/00. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Feb 24 2026 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).